A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
Study Identifier:
ALXN1840-HV-107
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
- Drug: Placebo
- Drug: Moxifloxacin
Date
Jul 2020 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 50 Years
Requirements Information
Sex
Female & Male
Age
18 - 50 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
- Drug: Placebo
- Drug: Moxifloxacin
Date
Jul 2020 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 50 Years years
Requirements Information
Protocol Summary
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
Trial Locations
Location
Status
Location
PPD Development, LP
Austin, Texas, United States, 78744
Status
N/A